Novo Integrated Sciences (Novo Integrated Sciences) Risk Assessment

View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Novo Integrated Sciences is: High Risk: High uncertainty.

Competitive Comparison of Novo Integrated Sciences's Risk Assessment

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Risk Assessment falls into.

Novo Integrated Sciences (NAS:NVOS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Novo Integrated Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004

Website

https://www.novointegrated.com

Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.

Executives

Sarfaraz Ali	director	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva	director	115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope	director	1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias	director	41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor	director	49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione	director, 10 percent owner, officer: Chief Executive Officer	79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt	director, 10 percent owner	35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David	director, officer: President	10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald	officer: Chief Accounting Officer	1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters	director	1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse	officer: secretary	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden	officer: President & CEO	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo	director	1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724